Skip to main content

Table 2 Organ Gb3a levels 26 weeks postinjection (Experiment 1)

From: α-Galactosidase A-Tat Fusion Enhances Storage Reduction in Hearts and Kidneys of Fabry Mice

Gb3 levels (nmol/mg protein)
  Liver Spleen Heart Kidney Lung
PBS 13.4 ± 0.8 (n = 7) 18.4 ± 1.8 (n = 4) 8.8 ± 1.0 (n = 6) 29.8 ± 1.5 (n = 7) 59.1 ± 6.5 (n = 7)
LV/enGFP 15.4 ± 2.0 (n = 5) 11.9 ± 1.3 (n = 4) 5.1 ± 0.5 (n = 3) 28.6 ± 7.1 (n = 5) 8.3 ± 1.4b (n = 3)
LV/α-gal A 1.0 ± 0.1 (n = 8) 2.8 ± 1.2 (n = 6) 1.3 ± 0.1 (n = 7) 17.2 ± 1.3 (n = 9) 12.4 ± 2.2 (n = 7)
LV/α-gal A-Tat 0.9 ± 0.2 (n = 8) 3.0 ± 0.6 (n = 8) 0.8 ± 0.1c (n = 6) 8.2 ± 1.7d (n = 9) 10.2 ± 0.7 (n = 7)
WTe 0.6 ± 0.2 (n = 5) 1.3 ± 0.1 (n = 5) 0.2 ± 0.1 (n = 4) 4.9 ± 1.6 (n = 5) 2.3 ± 0.6 (n = 3)
  1. aGb3, globotriaosylceramide.
  2. bLittle sample to analyze because of technical issues.
  3. cP < 0.05.
  4. dP < 0.01 vs LV/α-gal A group.
  5. eWT, wild type.